Efficacy, Safety and Pharmacokinetics of Oral NKTR-118 in Patients with Opioid-Induced Constipation: Results of a Randomized, Double-blind, Placebo-controlled Phase 2 Study
Lynn R. Webster(Adherent Technologies (United States)), Teressa Patrick(University of Dayton), Richard E. Blonsky(Shirley Ryan AbilityLab), René Martz(Hamburg Institut (Germany)), Sunita Dhar(Nektar Therapeutics (United States)), D. Levinsky(Azienda Mobilità e Trasporti), Michael A. Eldon(Nektar Therapeutics (United States)), THERESA NEUMANN(Nektar Therapeutics (United States)), Paul G. Matz(University of California, San Francisco)
Cited by 6
Related Papers
Predicting Aberrant Behaviors in Opioid-Treated Patients: Preliminary Validation of the Opioid Risk Tool
|Pain Medicine|2005|1.1k
Risk Factors for Opioid-Use Disorder and Overdose
|Anesthesia & Analgesia|2017|504
Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain
|New England Journal of Medicine|2014|331
Sleep-Disordered Breathing and Chronic Opioid Therapy
|Pain Medicine|2007|309
A Randomized, Double-Blind, Placebo-Controlled Study of Intrathecal Ziconotide in Adults with Severe Chronic Pain
|Journal of Pain and Symptom Management|2006|304